Bone lymphoma treatment

PubMed, the Internet portal of biomedical and life sciences literature, indexed an interesting article, entitled “Dramatical improvement of chemoresistant bone lymphoma with rituximab” (Clin Rheumatol. 2005 Oct 25;:1-2). Authors are Achemlal L, Mikdame M, Nouijai A at al., from Rheumatology and Physical Rehabilitation Department, Military Hospital Mohammed V, Rabat, Morocco. Non-Hodgkin’s lymphoma of the bone is a very rare disease that accounts for approximately 5% of all extranodal non-Hodgkin’s lymphomas and for 7-10% of primary bone tumours. The authors report the case of a 28-year-old man with diffuse, large B-cell non-Hodgkin’s lymphoma. The patient received six cycles of conventional chemotherapeutic regimen. His arm pain worsened, and x-rays demonstrated progressive disease. He began a trial of rituximab, for 4 weeks. There was improvement in pain after the first infusion. Radiographic studies conducted 3 months after rituximab therapy showed marked improvement in his humerus disease. He had no evidence of recurrent lymphoma 24 months later. To access the full abstract of the article, click here.